Physician profile
Jeevana K Krishna
NPI 1528020575
$7,717.49
in general payments reported to CMS, 2019-2025
47 companies · $539 in 2025
The $539 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $636 · 2020: $1,117 · 2021: $2,657 · 2022: $1,035 · 2023: $992 · 2024: $742 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,272.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,289.22 | 2021 | |
| Abbvie INC. | $973.23 | 2019-2025 | |
| Astellas Pharma US INC | $672.34 | 2019-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $623.82 | 2020-2024 | Mounjaro |
| Novo Nordisk INC | $580.86 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $408.83 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Paratek Pharmaceuticals, INC. | $241.44 | 2020-2023 | Nuzyra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $207.33 | 2022-2025 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $205.59 | 2019-2023 | Livalo |
| Pfizer INC. | $194.15 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $190.73 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $178.31 | 2019-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $166.72 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $160.03 | 2019-2023 | Breztri, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $147.36 | 2019-2025 | Xifaxan |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeevana Krishna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.